Inici › Càncer de bufeta › Carolina del Nord › Durham
Assaigs clínics de Càncer de bufeta a Durham, NC
20 estudis de Càncer de bufeta busquen participants en centres de Durham i voltants (en un radi d'uns 30 milles). Obre un estudi per veure qui hi pot participar i com contactar amb l'equip.
Text oficial de l'estudi (anglès)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
ReclutantEstudi observacionalVoluntaris sans benvinguts
- Durham VA Medical Center, Durham
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
ReclutantFase 2
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · a 10 mi
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
ReclutantFase 2
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · a 10 mi
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
ReclutantFase 1/2
- Duke University Medical Center (location of scans), Durham
- Duke University Medical Center - Duke University Hospital (location of scans), Durham
- Duke University Medical Center, Durham
- i 1 més
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
ReclutantFase 1
- Biorepository and Precision Pathology Center (BRPC), Durham
- Duke Cancer Institute, Durham
- Substrate Services Core Research Support (SSCRS), Durham
DESTINY-PANTUMOUR04
ReclutantEstudi observacional
- Research Site, Durham
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
ReclutantFase 1
- Duke University Medical Center - Duke Cancer Center, Durham
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
ReclutantEstudi observacional
- UNC- Chapel Hill, Chapel Hill · a 10 mi
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
ReclutantFase 2
- University of North Carolina, Chapel Hill · a 10 mi
The Vanguard Study: Testing a New Way to Screen for Cancer
ReclutantVoluntaris sans benvinguts
- Durham VA Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · a 10 mi
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
ReclutantFase 1
- University of North Carolina (UNC) - Chapel Hill, Chapel Hill · a 10 mi
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
ReclutantFase 2/3
- Research Site, Chapel Hill · a 10 mi
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
ReclutantFase 3
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · a 10 mi
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
ReclutantFase 1/2
- Duke Health - Duke Cancer Center, Durham
- UNC Chapel Hill Hospital, Chapel Hill · a 10 mi
Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2
ReclutantEstudi observacional
- University of North Carolina, Chapel Hill · a 10 mi
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
ReclutantFase 2
- UNC Hospitals, The University of North Carolina at Chapel Hill, Chapel Hill · a 10 mi
- UNC Lineberger Comprehensive Cancer Center / University of North Carolina, Chapel Hill · a 10 mi
PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
Reclutant
- Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill · a 10 mi
Characterizing the Microvascular Environment of Bladder Cancer With Super-Resolution Ultrasound Localization Microscopy
ReclutantEstudi observacional
- Duke University, Durham
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
ReclutantFase 1
- Duke Cancer Institute, Durham
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
ReclutantEstudi observacional
- Massive Bio SYNERGY-AI site, Chapel Hill · a 10 mi
Assaigs de Càncer de bufeta en altres ciutats
- New York City, NY35 estudis
- Nashville, TN31 estudis
- Houston, TX31 estudis
- Dallas, TX27 estudis
- Boston, MA26 estudis
- Washington, DC26 estudis
- Los Angeles, CA24 estudis
- Baltimore, MD24 estudis
- St. Louis, MO22 estudis
- Philadelphia, PA21 estudis
- Seattle, WA21 estudis
- Edison, NJ21 estudis
Altres estudis a Durham
- Càncer de mama63 estudis
- Càncer (tots els tipus)58 estudis
- Càncer de pulmó de cèl·lules no petites39 estudis
- Mieloma múltiple37 estudis
- Càncer metastàtic33 estudis
- Leucèmia mieloide aguda33 estudis
- Càncer de pulmó32 estudis
- Càncer de pròstata32 estudis
- Càncer colorrectal28 estudis
- Leucèmia limfàtica crònica27 estudis
- Càncer d'ovari27 estudis
- Insuficiència cardíaca26 estudis
De ClinicalTrials.gov, dades recuperades el 5 d’oct. 2026. Cada estudi estableix els seus propis criteris d'elegibilitat; l'equip de l'estudi decideix qui hi pot participar.